A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC

Viscardi, Giuseppe; Sparano, Francesca; Liello, Raimondo Di; Casal, G. Alonso; Ferreres, R. Borras; Bruixola, Gema; Gambardella, Valentina; Zanaletti, N.; Iacovino, Maria Lucia; Corte, C. Mlla De; Papaccio, Federica; Fasano, Morena; Ciardiello, Fortunato; Cervantes, A.; Morgillo, Floriana; Martorell, P; Mollá, M A

doi:10.1093/annonc/mdz449.040

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, patients with high AEC had a higher Objective Response Rate (ORR) (40.9% versus 28.8%, P=0.029) and longer PFS (8.93 months versus 5.87 months, P=0.038) [85]. In a review by Zen et al [98] in analyzing mechanisms behind ICI-induced liver injury which is considered a new form of liver disease emerging in the era of cancer immunotherapy noted that mainly lymphocytes and occasional eosinophils infiltrated the liver resulting to liver injury [99][100][101][102][103][104][105][106] (Table 2).…”

Section: Eosinophils and Association With The Development Of Iraesmentioning

confidence: 99%

The Potential Role of Circulating Inflammatory Cells in Predicting the Safety, Efficacy and Immune-related Adverse Events of Immune Check-point Inhibitors: A Narrative Review

K Rugambwa

2023

GMR

View full text Add to dashboard Cite

Immune checkpoint blockade has influenced the course of cancer treatment with improved Overall Survival (OS) and durable responses in many malignancies. Despite these responses, their mechanism of action has brought different set of adverse events that are severe and life-threatening in a subset of patients. Moreover, not all patients have shown to benefit from this treatment although their tumors express U.S. Federal and Drug Administration (FDA) approved biomarkers i.e programmed cell Death Protein 1 (PD-1) and its ligand (PD-L1), Microsatellite Instability (MSI) and Tumor Mutation Burden (TMB). Limitations of these markers has stimulated further research to identify and incorporate other markers that could serve as an adjunct to the current approved ones. Circulating inflammatory cells are among biomarkers that have shown to have a prognostic and predictive value in determining treatment response to Immune Checkpoint Inhibitors (ICI) and risk of Immune-Related Adverse Events (irAEs). This review aims to provide more details on the key inflammatory cells that play a pivotal role in cancer progression and inhibition and how their interaction in the tumor micro-environment (TME) affects response to immune checkpoint blockade and predicting irAEs. Moreover examples of prognostic models that have incorporated these cells will be highlighted.

show abstract

Section: Eosinophils and Association With The Development Of Iraesmentioning

confidence: 99%

The Potential Role of Circulating Inflammatory Cells in Predicting the Safety, Efficacy and Immune-related Adverse Events of Immune Check-point Inhibitors: A Narrative Review

K Rugambwa

2023

GMR

View full text Add to dashboard Cite

show abstract

A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC

Cited by 1 publication

References 0 publications

The Potential Role of Circulating Inflammatory Cells in Predicting the Safety, Efficacy and Immune-related Adverse Events of Immune Check-point Inhibitors: A Narrative Review

The Potential Role of Circulating Inflammatory Cells in Predicting the Safety, Efficacy and Immune-related Adverse Events of Immune Check-point Inhibitors: A Narrative Review

Contact Info

Product

Resources

About